Clinical trials: sponsored by The Netherlands Cancer Institute
Breast Cancer
Substantially Improving the Cure Rate of High-risk BRCA1-like Breast Cancer
Investigator-initiated, international, multicentre, randomized, open-label, (neo)adjuvant phase III study in target population (stage III, HER2-negative, BRCA1-like breast cancer patients) comparing optimized standard-dose…
- Trial name
- Subito (NCT02810743)
- Testing
- ddAC-CP-Olaparib, ddAC-mini CTC
- Where
- 11 sites in France, Netherlands
- Volunteers
- 174 people
- Sponsor
- The Netherlands Cancer Institute
Sarcoma
Assessing Health-related Quality of Life in Sarcoma Patients
Although the clinical effectiveness of sarcoma treatment has improved, long-lasting and cumulative treatment side-effects may often detract from the overall marginal advantage.
- Trial name
- NCT04071704
- Where
- 3 sites in Germany, Jordan
- Volunteers
- 654 people
- Sponsor
- The Netherlands Cancer Institute
Gastrointenstinal Stromal Tumor (GIST)
Long-term Survivorship Challenges of Advanced/Metastatic GIST Patients Responding to Tyrosine Kinase Inhibitor Treatment: an Observational Study
Gastrointestinal stromal tumours (GISTs) are rare malignancies arising along the gastrointestinal tract. Tyrosine kinase inhibitors (TKIs) have substantially improved survival for patients with unresectable or metastatic GIST.
- Trial name
- NCT07522762
- Where
- Netherlands
- Volunteers
- 330 people
- Sponsor
- The Netherlands Cancer Institute
Ovarian Cancer
Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
stage III epithelial ovarian cancer randomizing between primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy
- Trial name
- OVHIPEC-2 (NCT03772028)
- Testing
- cisplatin
- Where
- 28 sites in United States, Denmark and 5 more
- Volunteers
- 538 people
- Sponsor
- The Netherlands Cancer Institute
Triple Negative Breast Cancer (TNBC), Early Setting, Early Stage Triple-Negative Breast Carcinoma
Pembrolizumab Adjuvant in Patients With Early-stage Triple Negative Breast Cancer With Residual Disease After Neoadjuvant Pembrolizumab Plus Chemotherapy
The phase III, multicenter, pragmatic PLANET trial aims to evaluate the benefit and safety of pembrolizumab as an addition to standard of care adjuvant treatment (capecitabine or olaparib) in triple negative breast cancer (TNBC)…
- Conditions
- Triple Negative Breast Cancer (TNBC), Early Setting, Early Stage Triple-Negative Breast Carcinoma, Triple -Negative Breast Cancer, Breast Cancer Stage II
- Trial name
- PLANET (NCT07486687)
- Testing
- Standard of care plus pembrolizumab, Standard of care (capecitabine or olaparib)
- Volunteers
- 1,000 people
- Sponsor
- The Netherlands Cancer Institute
Carcinoma, Non-Small-Cell Lung
Anti-PD-1 Re-challenge After Immune Priming by Ipilimumab and Immune Boosting by Radiotherapy in Advanced NSCLC
Still many advanced non-small cell lung cancer (NSCLC) patients do not benefit from PD-(L)1 inhibition or will eventually develop progression through secondary resistance.
- Trial name
- RAD-IO (NCT05401786)
- Testing
- Ipilimumab, Cemiplimab, SBRT
- Where
- Netherlands
- Volunteers
- 54 people
- Sponsor
- The Netherlands Cancer Institute
Ovarian Cancer, Epithelial Cancer
The PROOV Study: Exploiting the Synergistic Effect of PARP Inhibition With Cisplatin and Hyperthermia During Interval Cytoreductive Surgery and HIPEC in Ovarian Cancer
The PROOV study is an open-label, monocenter, single-arm, prospective phase I/II trial with a safety lead-in, evaluating the feasibility of combining PARPi with HIPEC in stage III EOC patients.
- Conditions
- Ovarian Cancer, Epithelial Cancer, Fallopian Tube Cancer
- Trial name
- PROOV (NCT07460180)
- Testing
- Olaparib
- Where
- Netherlands
- Volunteers
- 55 people
- Sponsor
- The Netherlands Cancer Institute
Resectable MMR-deficient Solid Tumors, Resectable MMR-proficient Solid Tumors
Pan-tumor Neoadjuvant Basket Study of Immune Check-point Inhibition and Novel Immuno-oncology Combinations
In this study, the efficacy of botensilimab and balstilimab in mismatch repair deficient (dMMR) and mismatch repair proficient (pMMR) tumors will be assessed.
- Trial name
- NEOASIS (NCT06279130)
- Testing
- botensilimab, balstilimab, FLOT (Fluorouracil+Leucovorin+Oxaliplatin+Docetaxel)
- Where
- Netherlands
- Volunteers
- 133 people
- Sponsor
- The Netherlands Cancer Institute
NSCLC Stage IV
18F-PD-L1 PET/CT in Nivolumab Treated Patients With NSCLC
A multicenter single arm biomarker exploration and validation study. Eighty patients with NSCLC that are eligible for first line chemo-immunotherapy, first line nivolumab/ipilimumab or 2nd line and beyond PD-(L)1 immunotherapy…
- Trial name
- NCT03564197
- Testing
- 18F-PD-L1
- Where
- 8 sites in Netherlands
- Volunteers
- 80 people
- Sponsor
- The Netherlands Cancer Institute
Sarcoma of Soft Tissue, Sarcoma
Short Course of Radiotherapy Prior to Surgery of Soft Tissue Sarcomas
Based upon the preliminary data derived from first SCOPES clinical trial and the results of patients treated during the recent COVID-19 pandemic, patients with soft tissue sarcomas (STS) can be preoperatively irradiated in a…
- Conditions
- Sarcoma of Soft Tissue, Sarcoma, Sarcoma, Soft Tissue
- Trial name
- SCOPES II (NCT07071727)
- Testing
- Preoperative radiotherapy
- Where
- 6 sites in Netherlands
- Volunteers
- 150 people
- Sponsor
- The Netherlands Cancer Institute
Prostate Cancer (Adenocarcinoma)
Dose De-escalation in Prostate Radiotherapy Using an MR-Linac in Two Fractions
The goal of this clinical trial is to find out whether lowering the radiation dose to parts of the prostate without visible tumor on MRI can reduce side effects while still effectively treating prostate cancer in men with low or…
- Trial name
- DESTINATION 2 (NCT07391982)
- Testing
- uniform dose radiotherapy, De-escalated dose radiotherapy
- Where
- Netherlands
- Volunteers
- 54 people
- Sponsor
- The Netherlands Cancer Institute
Head and Neck Cancer
Lymph Drainage Mapping for Tailoring Elective Nodal Irradiation in Head and Neck Cancer
This study aims to explore the safety and outcome of lymph drainage mapping(LDM) to individually tailor the elective nodal irradiation (ENI) to the ipsilateral neck only.
- Trial name
- SUSPECT-2 (NCT03968679)
- Testing
- Unilateral elective nodal irradiation
- Where
- Netherlands
- Volunteers
- 90 people
- Sponsor
- The Netherlands Cancer Institute
DCIS
Management of Low-risk (Grade I and II) DCIS
A substantial number of DCIS lesions will never form a health hazard, particularly if it concerns slow-growing low-risk DCIS (grade I and II).
- Trial name
- LORD (NCT02492607)
- Testing
- Standard treatment, digital mammography, radiotherapy
- Where
- 60 sites in Netherlands
- Volunteers
- 2,500 people
- Sponsor
- The Netherlands Cancer Institute
Soft Tissue Sarcoma Adult
Sarcomas and DDR-Inhibition; a Combined Modality Study
To assess the safety and tolerability profile, in the pre- and perioperative period (up to 30 days post-surgery), of combined modality treatment (CMT) by administering AZD1390 with or without durvalumab and RT concurrently…
- Trial name
- SADDRIN-1 (NCT05116254)
- Testing
- AZD1390 + radiotherapy, AZD1390 + durvlaumab + radiotherapy
- Where
- Netherlands
- Volunteers
- 12 people
- Sponsor
- The Netherlands Cancer Institute
Renal Cancer, Partial Nephrectomy
Navigated Partial Nephrectomy
This study aims to evaluate electromagnetic (EM) tracked navigation in robot-assisted partial nephrectomy (RAPN), addressing kidney movement issues by attaching a tracked EM sensor close to the lesion.
- Trial name
- NCT07315100
- Testing
- Image guided surgery
- Where
- Netherlands
- Volunteers
- 20 people
- Sponsor
- The Netherlands Cancer Institute
Melanoma, Breast Cancer
Contrast-enhanced Ultrasound for Sentinel Node Detection
This is a prospective single-center interventional non-inferiority study where subjects are participating for one day for patients 18 years or older with melanoma, breast cancer or head \& neck cancer (including melanoma of head…
- Conditions
- Melanoma, Breast Cancer, Head & Neck Cancer
- Trial name
- NCT07310758
- Testing
- Sonazoid
- Where
- Netherlands
- Volunteers
- 91 people
- Sponsor
- The Netherlands Cancer Institute
Abdominal Cancer
Vessel- and Bone-based Ultrasound Registration
In this study we aim to develop an automatic artery and bone segmentation algorithm, which is required for future clinical implementation of US registration for surgical navigation.
- Trial name
- NCT05637346
- Testing
- Intra-operative ultrasound measurement
- Where
- Netherlands
- Volunteers
- 50 people
- Sponsor
- The Netherlands Cancer Institute
Cisplatin-related Hearing Loss
Transtympanic STS Against Cisplatin-induced SNHL: the SOUND Trial
The goal of this clinical trial is to learn if transtympanic sodium thiosulfate (STS) injections can prevent hearing loss caused by cisplatin chemotherapy in adults with head and neck cancer.
- Trial name
- SOUND (NCT07281508)
- Testing
- Transtympanic sodium thiosulphate (STS) 0.1M/0,5% hyaluronate
- Where
- 5 sites in Netherlands
- Volunteers
- 100 people
- Sponsor
- The Netherlands Cancer Institute
Prostatic Neoplasm
EBRT + Lu-PSMA for N1M0 Prostate Cancer
The PROQURE project aims to provide prostate cancer patients with more cure and better quality of life. The first part of this project (PROQURE-1) aims to explore an innovative combined modality treatment strategy for patients…
- Trial name
- PROQURE-1 (NCT05162573)
- Testing
- 177Lu-PSMA-617, EBRT
- Where
- 2 sites in Netherlands
- Volunteers
- 14 people
- Sponsor
- The Netherlands Cancer Institute
Colorectal Cancer
Pembrolizumab for Locally Advanced, Irresectable, Non-metastatic dMMR Colorectal Cancers
In this study, the efficacy of pembrolizumab in patients with locally advanced, irresectable dMMR colorectal cancer will be assessed.
- Trial name
- PUMA (NCT05131919)
- Testing
- Pembrolizumab
- Where
- Netherlands
- Volunteers
- 25 people
- Sponsor
- The Netherlands Cancer Institute